For years, severe allergy sufferers have used needle-based epinephrine autoinjectors like the EpiPen. Now, the FDA has approved Neffy, a needle-free intranasal epinephrine spray for treating anaphylaxis. While the release date is still pending, Centra pharmacist Daniel Nassif provides insights for those considering this new option.
Who is Neffy's target audience?
- Currently, Neffy is only approved for individuals who weigh at least 30kg (66 lbs.) and are experiencing an allergic reaction.
- Neffy is an excellent option for parents to administer to children without requiring a needle stick.
What are some pros and cons of using Neffy?
- One of Neffy's most significant benefits is that it is the first needle-free device. Some patients or caregivers may not feel comfortable using a potentially life-saving medication because it requires the use of needles.
- Neffy is simple to use: You deliver a single dose into one nostril, although a second dose may be needed if the patient doesn’t improve, or their symptoms worsen.
- Neffy should be used cautiously in patients with certain nasal conditions, such as polyps or a history of nasal surgery. It may affect the absorption so that the injectable product may be preferable. Patients should discuss this with their provider.
- Neffy will have an expiration date, as required by the FDA; however, it is unclear how long the shelf life will last or how it compares to the EpiPen’s status.
If you are considering Neffy, please talk to your provider to discuss what options are best for you.
